Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus reduced-dose cyclosporine versus mycophenolic acid plus standard-dose cyclosporine for CMV prevention after kidney transplantation
2013-003195-12Phase 4Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Jun 2015
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in cytomegalovirus disease (CMV) comparing Everolimus + reduced-dose cyclosporine with Mycophenolic acid + standard-dose cyclosporine (2 arms). Started Jun 2015; status: active.
02
Drugs
everolimusmycophenolate sodiumcyclosporine
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on 2013-003195-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003195-12.